•Robert Swanson and Dr. Herbert Boyer founded Genentech on April 7.
•Genentech produced the first human protein (somatostatin) in a microorganism (E. coli bacteria).
•Human insulin cloned by Genentech scientists.
•Human growth hormone cloned by Genentech scientists.
•Genentech went public and raised $35 million with an offering that leapt from $35 a share to a high of $88 after less than an hour on the market. The event was one of the largest stock run-ups ever.
•First recombinant DNA drug marketed: human insulin (licensed to Eli Lilly and Company).
•First laboratory production of Factor VIII, a clotting factor for bleeding in hemophiliacs. Genentech announced agreement to grant license of worldwide production and marketing of Factor VIII to Cutter Biological.
•Genentech received approval from the U.S. Food and Drug Administration (FDA) to market its first product, Protropin® (somatrem for injection) growth hormone for children with growth hormone deficiency — the first recombinant pharmaceutical product to be manufactured and marketed by a biotechnology company.
•Genentech's interferon alpha-2a — licensed to Hoffmann-La Roche, Inc. as Roferon®-A — received approval from the FDA for the treatment of hairy cell leukemia.
•Genentech instituted the Uninsured Patients Program, providing free growth hormone for financially needy, uninsured patients in the United States. The program was later expanded to include future products.
•Genentech received FDA approval to market Activase® (Alteplase, recombinant), a tissue-plasminogen activator (t-PA), to dissolve blood clots in patients with acute myocardial infarction (heart attack).
•Genentech opened its day-care center, Genentech's Second Generation, one of the largest corporate-sponsored day-care centers in the United States at the time.
Back to Top
•Genentech and Roche Holding Ltd. of Basel, Switzerland completed a $2.1 billion merger.
•Genentech's Hepatitis B vaccine — licensed to SmithKline Beecham Biologicals S.A. — received FDA approval.
•Genentech received FDA approval to market Activase for the management of acute massive pulmonary embolism (blood clots in the lungs).
Back to Top
•Genentech opened the Founders Research Center, dedicated to founders Robert Swanson and Dr. Herbert Boyer in appreciation of their vision and determination to pursue the promise of biotechnology.
Back to Top
•Genentech received FDA approval to market Nutropin® [somatropin (rDNA origin) for injection] for treating growth failure in children with chronic renal insufficiency before they undergo kidney transplantation.
•Genentech received approval to market Pulmozyme® (dornase alfa) for treating cystic fibrosis from regulatory agencies in the United States, Canada, Sweden, Austria and New Zealand.
•Genentech's Factor VIII — licensed to Miles Inc. (formerly Cutter Biological) in 1984 — received FDA approval for the treatment of hemophilia-A.
Agree ACTC is a great biotech but can't compare it to Genentech. Nonetheless, ACTC is taking the baby steps at this stage. Genetech might even end up buying it, if it continues to have positive blockbuster regenerative medicines (US patent #7736896, Myblast program)and excellent therapy clincial trials etc... etc..etc... Next two to three weeks will set the stage for a higher stock prices beyond these levels, and with many interested parties besides Big Pharma. Long.
Total hype.........EARLY phase I, zero other trials, zero product history, zero revenues, terrible history and management as confirmed by the 99% pps drop over a six-year period, AND
you say the next few weeks will draw interested parties like big pharma (as if big pharma has EVER spent a dime on a similarly-staged bio-tech).
You must be down, what, 50-80% to post such hype, hoping no one else will sell?
" Next two to three weeks will set the stage for a higher stock prices beyond these levels, and with many interested parties besides Big Pharma. "
Collaborate with WPC.........
Re: We close up for the day
by keep_investing.Dec 28, 2012 5:20 PM.Permalink
Lars, that sure was wrong, now you can become part of Wrong Predictors Club(WPC), a club Boos and I are charter members of.
The "correlation" is only a vague, broad scientific one. As one other person says, Genentech and Advanced Cell are doing different research.
But, not unlike stem cell applications and their promises (from stem cell transplantations of the various kinds, from the very easy to the very complex... to cellular programming, to tissue engineering), RECOMBINANT DNA and its promises have never matured into a totally reliable science, either, although modern day Recombinant DNA as a medical procurement was born some 40 years ago....
I think that's partly because Recombinant DNA is a "split" science, not fully into the modern day notion of pure gene therapy --- in the use of a person's own [or someone else's] genetic materials [proteins], in parcel and in whole genes, to cure genetic conditions --- and not fully into the traditional way of synthesizing molecular compounds as a means to either retard, stop, or poison bacteria and viruses....
With that in mind, I think Lanza and others, today, are much more focused on "purer" science: the application of human cells, genes, proteins, and larger tissues and organs as a means to retarding, stopping, replacing, and/or regrowing damaged or missing cells, genes, proteins, and larger tissues and organs...
That is to say:
Cellular Therapies as they are pursued today, at least the way Advanced Cell is engaging in so far, rely totally on using the body's own cells and other bodily materials as the vehicle to combat GENETIC DISEASES, as well as to replace, repair, or regrow damaged or missing human body parts---- from the individual cell level all the way to complete digits like fingers and toes, and other whole organs like noses, ears, etc.
MOLECULAR COMPOUNDS like immune suppressant drugs and other "pain killers" may be deployed, but only as enabling/facilitating compounds, not as the means by which the wounds, diseases, or condition to be healed...
Anyway, 20-50 years down the road, I think the convergence of recombinant DNA, gene therapy, and cellular programming will will truly usher in the next phase in medicine.
And powerful computational and bio-algorithmic methods will allow that convergence to happen.
That's when truly, virtually any tissue and organ in the human body --- except for whole brains --- that's (1) been worned out cells and organs, due to "normal" cellular breakdown, or, (2) damaged, due to diseases or accidents, can be readily regrown/replaced...
.... It's also when doctors will be able to take out, and/or insert into our chromosomal structure ---- and DO IT SAFELY with statistically significant confidence levels --- individual genes, proteins, and other necessary parts..... so that we can avoid developing many of the most debilitating genetic diseases (from both high in-breeding population groups and other more "natural" but deleterious mutational effect)....
In reality there is no correlation, for a number of reasons.
First and foremost, they had Axel Ullrich throughout that time. He may be considered one of the most important scientists in the 20th century, let alone one of the most important in biotech. Robert Lanza, for all his virtues, is not likely to make as massive an impact in our understanding of biology.
Second, Genentech was working in a time when recombinant technology was unknown and untested. Cloning a gene could get you a paper in nature. Nowadays if you want a paper to be published in Nature you will have performed hundreds of recombinant studies, at least in my field. The revolutionary technology Genentech brought to the table is now so common it's trivial.
Third, the two companies are quite dissimilar in their methodologies and goals. Just because they're both biotech does not mean they function the same way. ACTC could move a product to market faster than Genentech was able to, or their product could fail. Genentech's success has no correlation with ACTC's success.
OOOOPPPSSSS NO COMPARISON!!!!!
ACTC IS FASTER THAN LIGHTNING!!!
Under 30 sec. of READING ACTC UNIQUENESS!!! 26-Mar-11 07:46 pm
Lanza says ACT’s macular degeneration trial is likely to be significantly more straightforward. “The advantage, of course, is that we’re talking about a very small number of cells going into a very local area,” he says. Using instruments that can track a single retinal cell in the eye in real time, the researchers will also be able to easily monitor patients’ progress.
“Also, with the eyes there are very objective tests for visual acuity,” he notes, “so we can measure performance gains very objectively.” Tracking improvement after spinal cord injury, on the other hand, is notoriously tricky.
Sentiment : Strong Buy